Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant.
Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant.
复制标题
DOI:
10.1172/jci.insight.159944
复制
发表时间:
2022-10-10
期刊:
影响因子:
8
通讯作者:
Lemieux, Jacob E.
中科院分区:
文献类型:
--
作者:
Seaman, Michael S.;Siedner, Mark J.;Boucau, Julie;Lavine, Christy L.;Ghantous, Fadi;Liew, May Y.;Mathews, Josh I.;Singh, Arshdeep;Marino, Caitlin;Regan, James;Uddin, Rockib;Choudhary, Manish C.;Flynn, James P.;Chen, Geoffrey;Stuckwisch, Ashley M.;Lipiner, Taryn;Kittilson, Autumn;Melberg, Meghan;Gilbert, Rebecca F.;Reynolds, Zahra;Iyer, Surabhi L.;Chamberlin, Grace C.;Vyas, Tammy D.;Vyas, Jatin M.;Goldberg, Marcia B.;Luban, Jeremy;Li, Jonathan Z.;Barczak, Amy K.;Lemieux, Jacob E.
Protective immunity against SARS-CoV-2 infection after COVID-19 vaccination may differ by variant. We enrolled vaccinated (n = 39) and unvaccinated (n = 11) individuals with acute, symptomatic SARS-CoV-2 Delta or Omicron infection and performed SARS-CoV-2 viral load quantification, whole-genome sequencing, and variant-specific antibody characterization at the time of acute illness and convalescence. Viral load at the time of infection was inversely correlated with antibody binding and neutralizing antibody responses. Across all variants tested, convalescent neutralization titers in unvaccinated individuals were markedly lower than in vaccinated individuals. Increases in antibody titers and neutralizing activity occurred at convalescence in a variant-specific manner. For example, among individuals infected with the Delta variant, neutralizing antibody responses were weakest against BA.2, whereas infection with Omicron BA.1 variant generated a broader response against all tested variants, including BA.2.
登录
查看更多内容
影响因子:
7.8
作者:
Nunes MC;Mbotwe-Sibanda S;Baillie VL;Kwatra G;Aguas R;Madhi SA;On Behalf Of The Wits Vida Hcw Study Group
通讯作者:
On Behalf Of The Wits Vida Hcw Study Group
DOI:
10.1093/cid/ciab543
发表时间:
2022-03-09
期刊:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
影响因子:
--
作者:
Pollett SD;Richard SA;Fries AC;Simons MP;Mende K;Lalani T;Lee T;Chi S;Mody R;Madar C;Ganesan A;Larson DT;Colombo CJ;Colombo R;Samuels EC;Broder CC;Laing ED;Smith DR;Tribble D;Agan BK;Burgess TH
通讯作者:
Burgess TH
影响因子:
64.5
作者:
Hoffmann M;Krüger N;Schulz S;Cossmann A;Rocha C;Kempf A;Nehlmeier I;Graichen L;Moldenhauer AS;Winkler MS;Lier M;Dopfer-Jablonka A;Jäck HM;Behrens GMN;Pöhlmann S
通讯作者:
Pöhlmann S
影响因子:
15.9
作者:
Wang, Yanqun;Zhang, Lu;Zhao, Jincun
通讯作者:
Zhao, Jincun
DOI:
10.1056/nejmoa2105000
发表时间:
2021-06-10
期刊:
The New England journal of medicine
影响因子:
--
作者:
Hacisuleyman E;Hale C;Saito Y;Blachere NE;Bergh M;Conlon EG;Schaefer-Babajew DJ;DaSilva J;Muecksch F;Gaebler C;Lifton R;Nussenzweig MC;Hatziioannou T;Bieniasz PD;Darnell RB
通讯作者:
Darnell RB